Maria Raptis, P.C.

Life Sciences

• Catalent, Inc. in its acquisition by Novo Holdings A/S at an enterprise value of $16.5 billion*
• Livongo Health in its $18.5 billion sale to Teladoc*
• Gilead Sciences, Inc. in its:
  • $4.9 billion acquisition of Forty Seven*
  • $5.1 billion, 10-year global research and development collaboration and equity investment in Galapagos NV*
  • $11.9 billion acquisition of Kite Pharma, Inc.*
  • $11 billion acquisition of Pharmasset*
  • acquisition of Cell Design Labs for up to $567 million*
• Actavis in its $28 billion acquisition of Forest Laboratories and its $8.5 billion acquisition of Warner Chilcott*
• Array BioPharma in its $11.4 billion acquisition by Pfizer*
• Juno Therapeutics, Inc. in its $11 billion acquisition by Celgene Corporation*
• Iveric Bio in its $5.9 billion sale to Astellas*
• Dicerna Pharmaceuticals in its $3.3 billion sale to Novo Nordisk*
• BELLUS Health in its $2 billion sale to GSK*
• Pandion Therapeutics in its sale to Merck for $1.8 billion*
• CTI BioPharma in its $1.7 billion sale to Swedish Orphan Biovitrum (SOBI)*
• MorphoSys in its $1.7 billion acquisition of Constellation Pharmaceuticals and its related financing from Royalty Pharma totaling over $2 billion*
• Achillion Pharmaceuticals, Inc. in its $930 million acquisition by Alexion Pharmaceuticals, Inc.*
• Alcon in its $753 million acquisition of Aerie Pharmaceuticals*
• Mayne Pharma Group Limited in its $475 million sale of Metrics Contracts Services to Catalent, Inc.*
• Vertex Pharmaceuticals in its $320 million acquisition of ViaCyte*
• Ionis Pharmaceuticals in its acquisition of the remaining outstanding stake of Akcea Therapeutics for $500 million*
• ArQule in its sale to Merck for $2.7 billion*
• Alder BioPharmaceuticals in its sale to Lundbeck for up to $1.95 billion*
• CerSci Therapeutics in its sale to ACADIA Pharmaceuticals for up to $939.5 million*
• Stemline Therapeutics in its sale to Menarini Group for up to $677 million*
• Valeant in its acquisitions of Salix, Medicis, Dermik, Ortho Dermatologics and Biovail*
• Watson in its $5.9 billion acquisition of Actavis and its $1.9 billion acquisition of Andrx*

Technology and Media

• Activision Blizzard Inc. in its $75 billion acquisition by Microsoft Corporation, the largest-ever technology deal and the largest-ever gaming industry deal*
• Juniper Networks in its acquisition by Hewlett Packard Enterprise*
• Xilinx, Inc. in its $50 billion acquisition by Advanced Micro Devices, Inc.*
• Intelsat in its combination with SES*
• Splunk in its acquisition by Cisco*
• ZeniMax Media Inc. in its $7.5 billion acquisition by Microsoft Corporation*
• PayPal in its $4 billion acquisition of Honey Science Corporation and its strategic investments in MercadoLibre, Inc. and Uber Technologies, Inc.*
• Entegris in its $6.5 billion cash and stock acquisition of CMC Materials and the pending sale of its electronic chemicals business to Fujifilm for $700 million*
• NXP Semiconductors N.V. in its proposed-but-terminated $47 billion acquisition by Qualcomm Incorporated*
• Airbnb in its $400 million acquisition of Hotel Tonight*
• Intel Corporation in its:
  
  • $15.3 billion acquisition of Mobileye N.V.*
  • $1 billion sale of its modem business to Apple*
  • its proposed-but-terminated $5.4 billion acquisition of Tower Semiconductor*
• Hewlett Packard Enterprise Co. in its:
  
  • $1.3 billion acquisition of Cray Inc.*
  • $1 billion acquisition of Samsung’s printing business*
• Cineworld Group PLC in its $5.9 billion acquisition of Regal Entertainment Group*
• Carbonite, Inc. in its $1.4 billion acquisition by Open Text Corporation*
• Sophos Group plc with U.S. aspects of its $3.9 billion acquisition by Thoma Bravo, LLC*
• TiVo Inc. in its $1.1 billion acquisition by Rovi Corporation*
• NDS Group in its $5 billion acquisition by Cisco Systems*
• SanDisk in its $19 billion acquisition by Western Digital*

Financial Services

• Visa Inc. in its:
  
  • proposed-but-terminated $5.3 billion acquisition of Plaid Inc.*
  • $2.2 billion acquisition of Tink AB*
  • $1 billion acquisition of Pismo*
• First Bancorp. in its $1.1 billion acquisition of Banco Santander S.A.’s (Spain) Puerto Rico banking operations*

Other Experience

• Funds advised by Permira Advisers in numerous transactions*
• Funds advised by Apax Partners in numerous transactions*

*Prior to joining Kirkland